The effects of obstructive jaundice on the clinical pharmacokinetics of etomidate

The effects of obstructive jaundice on the Pharmacokinetics of etomidate

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007574

Enrollment

Unknown

Registered

2015-12-10

Start date

2015-12-21

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hilar cholangiocarcinoma, Pancreatic head carcinoma

Interventions

2:Etomidate

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Hilar cholangiocarcinoma, Pancreatic head carcinoma

Exclusion criteria

Exclusion criteria: Patients with known allergy to the study drugs, heart failure (ejection fraction <40%), and/or severe respiratory disease (vital capacity and/or forced expiratory volume <50%) preoperatively were excluded from this study

Design outcomes

Primary

Measure	Time frame
Plasma drug concentration;	—

Countries

China

Contacts

Public ContactJinchao Song

sjch2013@163.com+86 021-81875236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026